COMMUNIQUÉS West-GlobeNewswire

Light-it Group Launches Enlighten Ventures: A Micro-VC Initiative to Propel Healthtech Innovation

20/12/2024 - 14:35

Javier Lempert (CTO & Founder), Alan Brande (CEO & Founder) and Martin Oppenheimer (COO & Founder) at Light-it’s HQ. AVENTURA, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Light-it Group, a leading innovator in [...]

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

20/12/2024 - 14:05

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 Commitment is part of the European Investment Bank’s strategy [...]

Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

20/12/2024 - 14:00

ORANGE, Calif. , Dec. 20, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan [...]

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

20/12/2024 - 14:00

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]

Commure Acquires Memora Health, a Digital Care Navigation Platform, to Enhance Intelligent Care Navigation

20/12/2024 - 14:00

MOUNTAIN VIEW, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, announced today the acquisition of Memora Health (Memora), a digital care navigation platform. Memora will [...]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

20/12/2024 - 14:00

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177 Lu-RAD202 in Breast and Gastric Cancers The Phase 1 First-In-Human study is designed to assess the safety, tolerability [...]

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

20/12/2024 - 14:00

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a [...]

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

20/12/2024 - 14:00

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF” No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company [...]

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

20/12/2024 - 14:00

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a [...]

Aridis Provides Corporate Update

20/12/2024 - 14:00

LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments. Company [...]

Aspargo Labs Appoints General Managers in Spain and Germany to Drive International Expansion

20/12/2024 - 14:00

NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s most meaningful Rx and OTC medications into [...]

Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer

20/12/2024 - 13:50

SALINAS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, [...]

Novo Nordisk A/S - share repurchase programme

20/12/2024 - 13:47

Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

20/12/2024 - 13:30

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient [...]

Epitopea et Genevant Sciences annoncent une entente de collaboration

19/12/2024 - 22:35

CAMBRIDGE, Royaume-Uni et MONTRÉAL et VANCOUVER, Colombie-Britannique et BÂLE, Suisse, 19 déc. 2024 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique d’immunothérapies anticancéreuses qui met au point des [...]

Epitopea and Genevant Sciences Announce Collaboration Agreement

19/12/2024 - 22:30

CAMBRIDGE, United Kingdom and MONTREAL and VANCOUVER, British Columbia and BASEL, Switzerland, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the- [...]

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

19/12/2024 - 22:15

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: [...]

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

19/12/2024 - 22:10

AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and [...]

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

19/12/2024 - 22:08

- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell [...]